Repurposing Small Molecule Therapeutics to Prevent Cisplatin-Induced & Noise-Induced Hearing Loss
Time: 3:00 pm
day: Conference Day 1
Details:
- Preclinical studies with orally-delivered Dabrafenib for cisplatin-induced and noise-induced hearing loss
- Uncovering genetic mouse models for Debrafenib activity and the MAPK pathway
- Translation of repurposed FDA-approved small molecule drugs for prevention of hearing loss into clinical phase 1/2
